Author Archives: Julian Upton

Europe's IMI Looks to Portugal and Finland to Lead Scientific Committee

Europe’s Innovation Medicines Initiative (IMI) has appointed experts from Portugal and Finland to chair the IMI Scientific Committee. Professor Maria Beatriz da Silva Lima of the University of Lisbon in Portugal will be the new Chair; Professor Markus Perola of Finland’s National Institute for Health and Welfare was appointed Vice Chair. The IMI is the […]
Posted in Europe, Global | Tagged , , , , | Leave a comment

Big Pharma's "Firepower" Effectively Dropped by 20% in 2013, Says Report

Although Big Pharma’s ‘firepower’ increased last year by $100 billion, it declined in comparison with that of Big Biotech and specialty pharma, according to a new report from EY. EY’s Firepower Index measures companies’ capacity for conducting M&A deals. Firepower is diminished as its market value, cash and equivalents fall or as its debt levels […]
Posted in Strategy | Tagged , , , , | Leave a comment

EU Clinical Trials Agreement 'Compromised', Says Industry

European Union (EU) regulators reached agreement today on the much-vaunted Clinical Trials Regulation. The regulation harmonizes the rules for the conduct of clinical trials in the EU and the ‘acceptability’ of the resulting data, and palces further safeguards on the safety of trial subjects. The legislation’s aim is to facilitate and expedite the authorization procedure […]
Posted in Europe, Global, R&D, Regulatory | Tagged , , , , | Leave a comment

FDA Push for TRF Therapies Will 'Disrupt Pain Market'

FDA’s push for abuse-resistant opioid formulations will disrupt the pain market, say analysts Frost & Sullivan. The opioid market is currently dominated by non-tamper resistant formulations (TRFs), but FDA’s promotion of TRF therapies “could well result in the departure of non-TRF therapies from the market and shake up its structure.” Unless FDA mandates TRF therapies, […]
Posted in FDA, Safety, Strategy | Tagged , , , , | 1 Comment

Global Parkinson's Disease Market to Drop by $0.5 Billion by 2019, Says Report

The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY). With PD drugs such as Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone) set to lose their […]
Posted in Biotech | Leave a comment
  • Categories

  • Meta